Ph1 Marinol Interaction Study - Part 2 - 1
This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Liza Gorgon, National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00490269
First received: June 21, 2007
Last updated: April 8, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study will examine the effects of oral dronabinol tetrahydrocannabinol (THC) on withdrawal symptoms in marijuana dependent volunteers, and evaluate the safety, pharmacokinetics (PK), and cardiovascular effects of the combination of oral dronabinol and smoked marijuana to determine if there are potential significant drug interactions before conducting outpatient studies.
| Condition | Intervention | Phase |
|---|---|---|
|
Marijuana Dependence |
Drug: Placebo Drug: Dronabinol |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) |
| Official Title: | Phase 1, Pilot Study to Examine the Cardiovascular Effects of Smoked Marijuana, Interactions With Oral Dronabinol, and Effects of Dronabinol on Withdrawal in Marijuana Dependent Volunteers |
Resource links provided by NLM:
Further study details as provided by National Institute on Drug Abuse (NIDA):
Primary Outcome Measures:
- Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects. [ Time Frame: Day 9 and 10 ] [ Designated as safety issue: Yes ]Does dronabinol (when given during smoking of a marijuana cigarette) show changes in the number of participants that experience cardiovascular effects of smoked marijuana or has any other combination side effects.
| Enrollment: | 12 |
| Study Start Date: | October 2006 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Dronabinol |
Drug: Dronabinol
Other Name: Medication intervention
|
| Placebo Comparator: Placebo |
Drug: Placebo
Other Name: Placebo comparator arm
|
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Must be between 18 and 45 years of age
- Must be in good general health and who meet DSM-IV diagnostic criteria for marijuana dependence
- Must be seeking treatment at time of study entry
- Must be able to understand and provide written informed consent
- Must provide 1 marijuana positive urine specimen (> 50 ng/mL) within the 28-day screening period
- If female and of child bearing potential, agrees to use birth control.
Exclusion
Criteria:
- Please contact site for more information
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00490269
Locations
| United States, Maryland | |
| Uniformed Services University of Health Science | |
| Bethesda, Maryland, United States, 20814 4799 | |
Sponsors and Collaborators
Investigators
| Principal Investigator: | Louis Cantilena, M.D. | Uniformed Services University of Health Science |
More Information
No publications provided
| Responsible Party: | Liza Gorgon, NIDA Project Officer, National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00490269 History of Changes |
| Other Study ID Numbers: | NIDA-CPU-0013-1 |
| Study First Received: | June 21, 2007 |
| Results First Received: | December 19, 2012 |
| Last Updated: | April 8, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Marijuana Abuse Substance-Related Disorders Mental Disorders Tetrahydrocannabinol Hallucinogens Physiological Effects of Drugs Pharmacologic Actions |
Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 23, 2013